FDA Approves Gilead's First-Ever Chronic HDV Drug for U.S. Market
GILD sits 28% above its 52-week low of $104.46.
Summary
The FDA has granted accelerated approval to Gilead Sciences' Hepcludex (bulevirtide-gmod) for chronic Hepatitis Delta Virus (HDV), marking the first approved treatment for this condition in the U.S. This approval addresses a critical unmet medical need for an estimated 40,000 to 80,000 patients in the U.S. and adds a new revenue stream to Gilead's portfolio. The drug is already available in Europe. This positive regulatory news follows Gilead's recent significant M&A activity and a revised full-year outlook to a net loss due to substantial IPR&D charges.
At the time of this announcement, GILD was trading at $134.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $166.6B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.